Hovione announced that the consolidated sales for the fiscal year ended March 2012 amounted to $180 million, the sixth consecutive year of sales growth, representing a growth of 24% in relation to last year.

In addition to the financial results, which reflect the quality of the Team's performance, overall 2011 represented a year of great achievements, namely:

Hovione stood behind 3 NDA approvals, these were all major NMEs - and in two cases the approvals were full QbD filings in which Hovione was central to the design and data generation.

All Hovione plants underwent several successful GMP inspections by one or more of the major Medicines' Agencies - a reflection of the large flow of filings and the high standards of compliance.